Screening for Ovarian Cancer

被引:34
作者
Cragun, Janiel Marie [1 ]
机构
[1] Univ Arizona, Dept Obstet & Gynecol, Tucson, AZ 85724 USA
关键词
HIGH-RISK; TRANSVAGINAL ULTRASOUND; MUTATION CARRIERS; FAMILY-HISTORY; TUMOR-MARKERS; CA125; WOMEN; SERUM; PROTEOMICS; SURVEILLANCE;
D O I
10.1177/107327481101800103
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ovarian cancer remains the most deadly of the gynecologic cancers. It is difficult to diagnose until in advanced stages. An effective screening test may help to decrease mortality from ovarian cancer. Due to the low incidence of ovarian cancer in the general population, a good screening test must have high sensitivity and specificity to allow accurate detection without excessive false-positive results. Thus, effective screening for ovarian cancer has remained elusive. Methods: Studies evaluating screening methods for ovarian cancer are reviewed. Screening methods investigated include ultrasound, CA-125, and serum proteins. Results: The use of CA-125 or ultrasound alone does not result in adequate sensitivity or specificity for routine screening. A combination of the two modalities improves sensitivity, specificity, and positive predictive value. Using a combination of serum proteins may also improve sensitivity, specificity, and positive predictive value, but such studies have yet to be validated. Conclusions: No effective screening methods for ovarian cancer that have been adequately validated are available. Routine screening for ovarian cancer in the general population is not currently recommended.
引用
收藏
页码:16 / 21
页数:6
相关论文
共 47 条
  • [11] New tumor markers: CA125 and beyond
    Bast, RC
    Badgwell, D
    Lu, Z
    Marquez, R
    Rosen, D
    Liu, J
    Baggerly, KA
    Atkinson, EN
    Skates, S
    Lokshin, A
    Menon, U
    Jacobs, I
    Lu, K
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 : 274 - 281
  • [12] Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial
    Buys, SS
    Partridge, E
    Greene, MH
    Prorok, PC
    Reding, D
    Riley, TL
    Hartge, P
    Fagerstrom, RM
    Chia, D
    Izmirlian, G
    Fouad, M
    Ragard, LR
    Johnson, CC
    Gohagan, JK
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 193 (05) : 1630 - 1639
  • [13] Proteomics and cancer - Running before we can walk?
    Check, E
    [J]. NATURE, 2004, 429 (6991) : 496 - 497
  • [14] Screening for Ovarian Cancer
    Clarke-Pearson, Daniel L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) : 170 - 177
  • [15] Genetic/Familial High-Risk Assessment: Breast and Ovarian Clinical Practice Guidelines in Oncology
    Daly, Mary B.
    Axilbund, Jennifer E.
    Buys, Saundra
    Crawford, Beth
    Farrell, Carolyn D.
    Friedman, Susan
    Garber, Judy E.
    Goorha, Salil
    Gruber, Stephen B.
    Hampel, Heather
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (05): : 562 - 594
  • [16] The search for predictive patterns in ovarian cancer: Proteomics meets bioinformatics
    Daly, MB
    Ozols, RF
    [J]. CANCER CELL, 2002, 1 (02) : 111 - 112
  • [17] Combined use of biomarkers for detection of ovarian cancer in high-risk women
    Donach, Martin
    Yu, Yinhua
    Artioli, Grazia
    Banna, Giuseppe
    Feng, Weiwei
    Bast, Robert C., Jr.
    Zhang, Zhen
    Nicoletto, Maria O.
    [J]. TUMOR BIOLOGY, 2010, 31 (03) : 209 - 215
  • [18] Fritsche HA, 1998, CLIN CHEM, V44, P1379
  • [19] Fung Michael Fung Kee, 2004, J Obstet Gynaecol Can, V26, P717
  • [20] Development of an ovarian cancer symptom index - Possibilities for earlier detection
    Goff, Barbara A.
    Mandel, Lynn S.
    Drescher, Charles W.
    Urban, Nicole
    Gough, Shirley
    Schurman, Kristi M.
    Patras, Joshua
    Mahony, Barry S.
    Andersen, M. Robyn
    [J]. CANCER, 2007, 109 (02) : 221 - 227